journal article·2009-07

Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles

Cheng-Liang Peng, Ping-Shan Lai, Feng-Huei Lin, Steven Yueh-Hsiu Wu, Ming-Jium Shieh

Biomaterials· Volume 30· Issue 21
Publisher page

Abstract

Chlorin-core star-shaped block copolymer (CSBC) may self-assemble to form micelles, which act as nanosized photosensitizing agents for photodynamic therapy (PDT) and further encapsulate hydrophobic drugs. This functionalized micellar delivery system is a potential dual carrier for the synergistic combination of photodynamic therapy and chemotherapy for the treatment of cancer. In this study, SN-38 encapsulated CSBC micelles were successfully prepared using a lyophilization-hydration method. Our results show that the prolonged plasma residence time of SN-38/CSBC micelles as compared with free CPT-11 permit increased tumor accumulation and consequently, improved antitumor activity. The combined effects of SN-38/CSBC micelles with PDT were evaluated in an HT-29 human colon cancer xenograft model. Interesting, SN-38/CSBC-mediated PDT synergistically inhibited tumor growth, resulting in up to 60% complete regression of well-established tumors after 3 treatments. These treatments also decreased the microvessel density (MVD) and cell proliferation within the subcutaneous tumors. Therefore, this SN-38/CBSC delivery system has the potential to offer dual therapies for the synergistic combination of PDT and chemotherapy for the treatment of cancer.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (52)

Show source-provided references
1. Photodynamic therapy for cancer10.1038/nrc1071 ↗
2. Photodynamic therapy: a means to enhanced drug delivery to tumors
3. Polyion complex micelles entrapping cationic dendrimer porphyrin: effective photosensitizer for photodynamic therapy of cancer10.1016/j.jconrel.2003.05.002 ↗
4. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy10.1016/j.jconrel.2007.06.012 ↗
5. Intracellular target for photo sensitization in cancer antiangiogenic photodynamic therapy mediated by polycation liposome10.1016/j.jconrel.2004.03.030 ↗
6. Improved photodynamic activity of porphyrin loaded into nanoparticles: an in vivo evaluation using chick embryos10.1016/j.ijpharm.2004.07.029 ↗
7. Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer10.1021/nl051679d ↗
8. Polyion complex micelles for photodynamic therapy: incorporation of dendritic photosensitizer excitable at long wavelength relevant to improved tissue-penetrating property10.1016/j.jconrel.2006.03.009 ↗
9. Biodegradable long-circulating polymeric nanospheres10.1126/science.8128245 ↗
10. Preparation and characterization of polymer micelles from poly(ethylene glycol)–poly(d,l-lactide) block copolymers as potential drug carrier10.1016/S0168-3659(99)00028-0 ↗
11. Micellar nanocontainers distribute to defined cytoplasmic organelles10.1126/science.1078192 ↗
12. Polymeric micelles as new drug carriers10.1016/S0169-409X(96)00401-2 ↗
13. Core-cross-linked polymeric micelles as paclitaxel carriers10.1021/bc034113u ↗
14. Targeted polymeric micelles for delivery of poorly soluble drugs10.1007/s00018-004-4153-5 ↗
15. Self-assembled star-shaped chlorine-core poly(ɛ-caprolactone)–poly(ethylene glycol) diblock copolymer micelles for dual chemo-photodynamic therapies10.1016/j.biomaterials.2008.05.018 ↗
16. Plant antitumor agents. I. Isolation and structure of camptothecin a novel alkaloidal leukemia and tumor inhibitor from Camptotheca Acuminata10.1021/ja00968a057 ↗
17. Structure–activity study of the actions of camptothecin derivatives on mammalian topoisomerase-I – evidence for a specific receptor-site and a relation to antitumor-activity
18. Topoisomerase I inhibitors: review and update10.1023/A:1008270717294 ↗
19. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer10.1016/S0140-6736(98)02309-5 ↗
20. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer10.1056/NEJM200009283431302 ↗
21. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer10.1056/NEJMoa003034 ↗
22. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer10.1038/sj.bjc.6600725 ↗
23. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer10.1200/JCO.2003.02.091 ↗
24. Phase-I and pharmacokinetic trial of weekly Cpt-1110.1200/JCO.1993.11.11.2194 ↗
25. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks10.1023/A:1013157727506 ↗
26. Possibility of active targeting to tumor tissues with liposomes10.1016/S0169-409X(99)00042-3 ↗
27. Influence of substitutions in asymmetric porphyrins on intracellular uptake, subcellular localization and phototoxicity in hela cells10.4015/S1016237208000556 ↗
28. Methoxy poly(ethylene glycol) and epsilon-caprolactone amphiphilic block copolymeric micelle containing indomethacin. II. Micelle formation and drug release behaviours10.1016/S0168-3659(97)00124-7 ↗
29. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors10.1158/0008-5472.CAN-06-1605 ↗
30. Inhibition of platelet-derived growth factor receptor phosphorylation by ST1571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model
31. Quantitative analysis of dose-effect relationships: the combined effects of multiple-drugs or enzyme-inhibitors10.1016/0065-2571(84)90007-4 ↗
32. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review10.1016/S0168-3659(99)00248-5 ↗
33. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor
34. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes10.1016/0005-2736(94)90038-8 ↗
35. Development and characterization of a novel liposome-based formulation of SN-3810.1016/j.ijpharm.2003.10.015 ↗
36. Enhanced cytotoxicity of saporin by polyamidoamine dendrimer conjugation and photochemical internalization10.1002/jbm.a.31760 ↗
37. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins
38. Camptothecins: a review of their development and schedules of administration10.1016/S0959-8049(98)00229-9 ↗
39. Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting10.1023/B:PHAM.0000048190.53439.eb ↗
40. Hepatic tissue distribution of doxorubicin-loaded nanoparticles after iv administration in reticulosarcoma m-5076 metastasis-bearing mice10.1007/BF02897257 ↗
41. Investigation into the role of macrophages in the formation and degradation of beta(2)-microglobulin amyloid fibrils10.1074/jbc.M705004200 ↗
42. Long-circulating and target-specific nanoparticles: theory to practice10.1016/S0031-6997(24)01494-7 ↗
43. Nanoparticles in cancer therapy and diagnosis10.1016/S0169-409X(02)00044-3 ↗
44. Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts10.1016/S0168-3659(99)00113-3 ↗
45. Enhanced photodynamic cancer treatment by supramolecular nanocarriers charged with dendrimer phthalocyanine10.1016/j.jconrel.2008.10.010 ↗
46. Photodynamic therapy: combined modality approaches targeting the tumor microenvironment10.1002/lsm.20339 ↗
47. Role of cytokines in photodynamic therapy-induced local and systemic inflammation10.1038/sj.bjc.6600864 ↗
48. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma
49. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors10.1158/0008-5472.CAN-05-1659 ↗
50. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy10.1158/1078-0432.CCR-04-2703 ↗
51. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)camptothecin, topotecan, and CPT-11 studied in the mouse cornea model
52. Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1 alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells10.1007/s00432-004-0642-z ↗